These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 33852233)

  • 1. A Retrospective Review of Patients' Response to Biologic Therapy for Psoriasis.
    Bagel J; Butler B; Nelson E; Hetzel A
    J Drugs Dermatol; 2021 Apr; 20(4):442-449. PubMed ID: 33852233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR).
    Mahil SK; Wilson N; Dand N; Reynolds NJ; Griffiths CEM; Emsley R; Marsden A; Evans I; Warren RB; Stocken D; Barker JN; Burden AD; Smith CH;
    Br J Dermatol; 2020 May; 182(5):1158-1166. PubMed ID: 31286471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Physician Global Assessment (PGA) and Psoriasis Area and Severity Index (PASI): why do both? A systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasis.
    Robinson A; Kardos M; Kimball AB
    J Am Acad Dermatol; 2012 Mar; 66(3):369-75. PubMed ID: 22041254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Prospective, Open-Label Study Evaluating Adjunctive Calcipotriene 0.005%/Betamethasone Dipropionate 0.064% Foam in Psoriasis Patients With Inadequate Response to Biologic Therapy.
    Bagel J; Zapata J; Nelson E
    J Drugs Dermatol; 2018 Aug; 17(8):845-850. PubMed ID: 30124723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
    Sbidian E; Chaimani A; Garcia-Doval I; Do G; Hua C; Mazaud C; Droitcourt C; Hughes C; Ingram JR; Naldi L; Chosidow O; Le Cleach L
    Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011535. PubMed ID: 29271481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjunctive Use of Calcipotriene/Betamethasone Dipropionate Foam in a Real-World Setting Curtails the Cost of Biologics Without Reducing Efficacy in Psoriasis.
    Bagel J; Nelson E; Zapata J; Hetzel A
    Dermatol Ther (Heidelb); 2020 Dec; 10(6):1383-1396. PubMed ID: 33048333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of weight reduction on treatment outcomes in obese patients with psoriasis on biologic therapy: a randomized controlled prospective trial.
    Al-Mutairi N; Nour T
    Expert Opin Biol Ther; 2014 Jun; 14(6):749-56. PubMed ID: 24661040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the efficacy of biologics versus conventional systemic therapies in the treatment of psoriasis at a comprehensive psoriasis care center.
    Au SC; Madani A; Alhaddad M; Alkofide M; Gottlieb AB
    J Drugs Dermatol; 2013 Aug; 12(8):861-6. PubMed ID: 23986158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Comparison of Psoriasis Severity in Pediatric Patients Treated With Methotrexate vs Biologic Agents.
    Bronckers IMGJ; Paller AS; West DP; Lara-Corrales I; Tollefson MM; Tom WL; Hogeling M; Belazarian L; Zachariae C; Mahé E; Siegfried E; Blume-Peytavi U; Szalai Z; Vleugels RA; Holland K; Murphy R; Puig L; Cordoro KM; Lambert J; Alexopoulos A; Mrowietz U; Kievit W; Seyger MMB;
    JAMA Dermatol; 2020 Apr; 156(4):384-392. PubMed ID: 32022846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term, real-world efficacy of biologics for psoriasis: a single centre's experience.
    Mercieca L; Lavery D; Warren RB; Griffiths CEM
    Br J Dermatol; 2019 Sep; 181(3):599-601. PubMed ID: 30738008
    [No Abstract]   [Full Text] [Related]  

  • 11. Efficacy and Safety of Calcipotriene 0.005%/Betamethasone Dipropionate 0.064% Foam With Apremilast for Moderate Plaque Psoriasis.
    Kircik LH; Schlesinger TE; Tanghetti E
    J Drugs Dermatol; 2020 Sep; 19(9):874-880. PubMed ID: 33026749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physician Global Assessment (PGA) and Psoriasis Area and Severity Index (PASI): why do both? A systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasis.
    Nast A; Schmitt J
    J Am Acad Dermatol; 2013 Jun; 68(6):1040-1. PubMed ID: 23680196
    [No Abstract]   [Full Text] [Related]  

  • 13. Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR]).
    Strober BE; Bissonnette R; Fiorentino D; Kimball AB; Naldi L; Shear NH; Goyal K; Fakharzadeh S; Calabro S; Langholff W; You Y; Galindo C; Lee S; Lebwohl MG
    J Am Acad Dermatol; 2016 May; 74(5):851-61.e4. PubMed ID: 26853180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Importance of Complete Skin Clearance in Psoriasis as a Treatment Goal: Implications for Patient-Reported Outcomes.
    Blauvelt A; Wu JJ; Armstrong A; Menter A; Liu C; Jacobson A
    J Drugs Dermatol; 2020 May; 19(5):487-492. PubMed ID: 32484628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriasis.
    Wu JJ; Pelletier C; Ung B; Tian M
    J Med Econ; 2019 Apr; 22(4):365-371. PubMed ID: 30652520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An open-label, prospective cohort pilot study to evaluate the efficacy and safety of etanercept in the treatment of moderate to severe plaque psoriasis in patients who have not had an adequate response to adalimumab.
    Vender R
    J Drugs Dermatol; 2011 Apr; 10(4):396-402. PubMed ID: 21455550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Durable dermatology life quality index improvements in patients on biologics associated with psoriasis areas and severity index: a longitudinal study.
    Chaptini C; Quinn S; Marshman G
    Australas J Dermatol; 2016 Aug; 57(3):e72-5. PubMed ID: 26010650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treating to Target-A Realistic Goal in Psoriasis?
    Gordon KB; Armstrong AW; Menter MA; Wu JJ
    Semin Cutan Med Surg; 2018 Feb; 37(2S):S44-S47. PubMed ID: 29614137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association Between Quality of Life and Improvement in Psoriasis Severity and Extent in Pediatric Patients.
    Bruins FM; Bronckers IMGJ; Groenewoud HMM; van de Kerkhof PCM; de Jong EMGJ; Seyger MMB
    JAMA Dermatol; 2020 Jan; 156(1):72-78. PubMed ID: 31774449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multinational, prospective, observational study to estimate complete skin clearance in patients with moderate-to-severe plaque PSOriasis treated with BIOlogics in a REAL world setting (PSO-BIO-REAL).
    Seneschal J; Lacour JP; Bewley A; Faurby M; Paul C; Pellacani G; De Simone C; Horne L; Sohrt A; Augustin M; Hammond E; Reich K
    J Eur Acad Dermatol Venereol; 2020 Nov; 34(11):2566-2573. PubMed ID: 32364296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.